The Boron–Neuron Connection: The Potential of Boron‐Containing Molecules for Treating Incurable Amyotrophic Lateral Sclerosis
ChemMedChem · 12.11.2026 · 21 (21)
DOI: 10.1002/cmdc.70554 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ChemMedChem, online erschienen am 27.10.2026. Verfasst von Nitesh Sanghai und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Neuroprotective Agents, Boron Compounds, Neurons. Die Arbeit nennt 239 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Canadian Institutes of Health Research (CIHR), Natural Sciences and Engineering Research Council of Canada (NSERC).
Abstract (Originalsprache)
Background
Boron (B), a group 13 metalloid, has emerged as a versatile element at the intersection of chemistry, biology, and medicine. Its electron‐deficient nature and ability to reversibly interconvert between trigonal planar ( sp 2 ) and tetrahedral ( sp 3 ) geometries enable dynamic covalent interactions with biological nucleophiles, making boron‐containing compounds (BCCs) attractive pharmacophores that selectively interact with reactive oxygen species (ROS) and are ROS‐responsive for therapeutic development. BCCs possess antioxidant, anti‐inflammatory, and metal‐chelating properties that make them attractive candidates for neurodegenerative diseases. Amyotrophic lateral sclerosis (ALS), a fatal and multifactorial motor neurodegenerative disorder, is characterized by oxidative stress, neuroinflammation, mitochondrial dysfunction, and metal dyshomeostasis, providing a strong rationale for exploring boron‐based therapeutics.
Methods
This review examines current literature on B chemistry, pharmacology, and translational applications, with emphasis on mechanisms relevant to ALS pathogenesis. This review focuses on ROS‐responsive B scaffolds, blood–brain barrier (BBB) permeability, neuroprotective mechanisms, hormonal modulation, metal chelation, and emerging preclinical evidence supporting boron‐based interventions.
Conclusions
BCCs represent a promising yet underexplored therapeutic platform for ALS and related neurodegenerative disorders. Their ROS‐responsive, redox‐modulating, and neuroprotective properties, combined with favorable CNS drug‐like pharmacokinetics, offer a mechanistically distinct approach to disease modification. Emerging preclinical evidence strongly supports further translational investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
ORCID-Profile: Nitesh Sanghai, Billy Vuong, Muhammad Shaharyar K Afridi, Sasha Leggett, Hemin Roghzai, Geoffrey K Tranmer
Förderung
- Canadian Institutes of Health Research (CIHR)
- Natural Sciences and Engineering Research Council of Canada (NSERC)
Zitieren
APA
Sanghai, N., Vuong, B., Afridi, M. S. K., Leggett, S., Roghzai, H., & Tranmer, G. K. (2026). The Boron–Neuron Connection: The Potential of Boron‐Containing Molecules for Treating Incurable Amyotrophic Lateral Sclerosis. ChemMedChem, 21(21). https://doi.org/10.1002/cmdc.70554
Vancouver
Sanghai N, Vuong B, Afridi MSK, Leggett S, Roghzai H, Tranmer GK. The Boron–Neuron Connection: The Potential of Boron‐Containing Molecules for Treating Incurable Amyotrophic Lateral Sclerosis. ChemMedChem. 2026;21(21). doi:10.1002/cmdc.70554
BibTeX
@article{Sanghai2026,
author = {Sanghai, Nitesh and Vuong, Billy and Afridi, Muhammad Shaharyar K and Leggett, Sasha and Roghzai, Hemin and Tranmer, Geoffrey K},
title = {The Boron–Neuron Connection: The Potential of Boron‐Containing Molecules for Treating Incurable Amyotrophic Lateral Sclerosis},
journal = {ChemMedChem},
year = {2026},
volume = {21},
number = {21},
doi = {10.1002/cmdc.70554}
}
EUVIMED